Company: Goldfinch Bio
Job title: Principle Scientist, Biomarker Development
Yossi Dagon, Ph.D. is the head of biomarker development at Goldfinch Bio. Dr. Dagon joined Goldfinch Bio in 2019 and together with his team, develops novel urinary biomarkers and technologies to stratify kidney disease patients based on molecular signatures and markers of treatment response, enabling a precision medicine approach to clinical development
Dr. Dagon is an author on more than 35 publications, a co-inventor on more than 15 issued U.S. patents and serves as a reviewer for several scientific journals.
Dr. Dagon received a Master’s degree in Cellular and Molecular Biology from Bar-Ilan University, Israel, a Ph.D. in Pharmacology from the Hebrew University of Jerusalem and completed his postdoctoral training at Harvard Medical school in Professor Barbara Kahn’s laboratory.
Utilizing Urinary Extracellular Vesicles as a Source of Biomarkers in Kidney Diseases 9:40 am
Urinary extracellular vesicles (uEVs) represent a promising noninvasive and readily available source of biomarkers for kidney diseases Signaling proteins in uEVs can serve as predictive biomarkers for kidney disease patients’ stratification Advances in technologies for uEVs isolation and analysis will accelerate the use of uEVs-based biomarkers in the clinicRead more
day: Day Two